Several abdominal aortic aneurysm (AAA) screening programs have been developed worldwide, aiming at early identification of individuals with an unknown AAA.
Several abdominal aortic aneurysm (AAA) screening programs have been developed worldwide, aiming at early identification of individuals with an unknown AAA. 1 This became possible because of the high accuracy (sensitivity and specificity of nearly 100%) of duplex scan, a noninvasive investigation performed by portable scanners. 2 Early detection of AAA allows a timely elective repair leading to a reduced AAA-related mortality and complications associated with an urgent intervention. 3, 4 A recent systematic evidence review for the US Preventive Services Task Force suggested that onetime invitation for AAA screening in men aged 65 years or older was associated with decreased AAA rupture and AAA-related mortality rates. 5 Another study highlighted the significant risk of AAA patients for developing cardiovascular (CV) events and thus the identification of those patients even with small AAA may contribute to CV risk reduction. 6 A recent meta-analysis showed that invitation to AAA screening in 64-year-old men significantly reduced both all-cause and AAA-related mortality. 7 The Society for Vascular Surgery (SVS) has recommended onetime duplex scan screening for AAAs in men aged 55 years or older with a family history of AAA, all men aged 65 years or older, and women aged 65 years or older who have smoked or have a family history of AAA. 8 In the United States, Medicare covers 1 ultrasound scan screening of men aged 65 to 75 years who ever smoked in their lifetime or men and women who have a family history of AAA disease as part of a "Welcome to Medicare" package. 9 The European Society for Vascular Surgery has recommended that men should be screened for AAAs with a single duplex scan at the age of 65 years or younger men who may be at increased risk (eg, those who smoke or have a family history). 10 On the other hand, although the American College of Preventive Medicine has recommended onetime screening in men aged 65 to 75 years who have ever smoked, it has not recommended routine screening in women. 11 Recent literature has highlighted the association of clinical factors with the increased incidence of AAA, which are not included in the indications of guidelines for AAA screening.
A total of 22 studies involving 13 388 patients concluded that AAA prevalence was significantly higher in patients with coronary artery disease versus patients without (odds ratio [OR] 2.42, 95% confidence interval [CI], 2.08-2.81).
12 Another meta-analysis showed that serum low-density lipoprotein cholesterol is higher in patients with AAA (mean differences [MD], 0.25 mmol/L; 95% CI, 0.08-0.42 mmol/L; P ¼ .004) than control patients while the serum high-density lipoprotein cholesterol is likely lower. 13 Additionally, a significant association between AAA and other factors has been demonstrated, such as body mass index (OR 1.20; 95% CI, 1.17-1.22), 14 chronic obstructive pulmonary disease (adjusted OR 3.0; 95% CI 1.6-5.5, P < .001), 15 primary abdominal wall hernia (OR 2.32; 95% CI, 1.72-3.14; P for effect <.00001; P for heterogeneity <.00001), 16 and the presence of simple renal cysts (OR 2.54; 95%CI, 1.93-3.34; P < .00001). 17 In contrast, diabetes mellitus (DM) appears to be inversely associated with prevalence of AAA, as shown in a pooled analysis of 13 studies which demonstrated that DM was significantly associated with lower prevalence of AAA (OR 0.59; 95% CI, 0.52-0.67; P < .00001). 18 Female gender has been neglected from most of the AAA screening programs except from the Chichester trial in which the AAA prevalence in females was 1.3%. 19 Apparently, this was based on the notion that the prevalence of AAA in females is too low to deserve inclusion in screening despite the fact that in the UK Small Aneurysm Trial (patients with AAA between 4.0 and 5.4 cm) women had a 3-fold increased rupture rate compared with men with equal diameter of AAA. 20 In a recent review, it was suggested that women undergo EVAR less often, mostly due to unfavorable neck anatomy, and tend to have a worse long-term outcome than in men. 21 Women were also less likely to undergo repair if their AAA ruptured; mortality was higher after repair, and ruptures occurred later in life. 21 It is of interest that the SVS recommends that women aged 65 years or older who have smoked or have a family history of AAA should be included in AAA screening programs. 6 In this context, a recent meta-analysis of the current prevalence of screen-detected AAA in women suggested that in women ever smokers and those >70 years of age the prevalence is >1%. 22 Therefore, it may be reasonable to this group of women.
The most recent screening programs with current indications have reported a lower incidence of AAA compared with the older ones. The incidence of AAA was 1.8% in the National Health Service (NHS) AAA screening program and 1.5% in the Swedish AAA screening program, 23 although a recent Belgian screening study showed the overall AAA prevalence to be 3.6%. 24 However, even with lower incidence, the screening programs have been shown to be effective in the detection and treatment of AAA and offer a clear balance of good over harm. 25 Thus, a population screening program is ethically justified, as long as men are given adequate information at every stage of the process. 26 However, using the current criteria for AAA screening, half of those with an AAA would never be eligible for inclusion in screening programs. 27 The existing data of the screening programs may not demonstrate the global truth of the AAA incidence as ethnic differences in CV risk factors exist. 28 Additionally, risk factor prevention strategies have not been developed with the same intensity worldwide. In many low-and middle-income countries (LMICs), morbidity and mortality associated with cardiovascular diseases (CVDs) have grown exponentially over the recent years. It is estimated that about 80% of CVD deaths occur in LMICs. 29 HEalthy LIfe in an Urban Setting (HELIUS), a multiethnic study, showed large treatment gaps in secondary prevention of CVD among 6 ethnic groups. 28 There are several ongoing AAA screening trials listed on ClinicalTrials.gov, for example, ultrasound AAA screening in Israeli Arab men who smoke (NCT02306304), populationbased screening study is evaluating the effect on mortality in an Asian population (NCT01205945), screening study in 65-year-old males in Norway (NCT01248533), and a randomized preventive vascular screening trial of 65-to 74-year-old men in Denmark (NCT00662480). However, none suggested targeted screening criteria in their protocol.
Future screening studies may also evaluate genetic factors in association with presence of AAA, as it has been suggested that polymorphisms in some genes had strong or moderate association with AAA. 30 While the cost-effectiveness of the current screening programs is obvious, population stratification to identify the most vulnerable based on novel risk factors may further increase their efficacy and reduce costs, especially in consideration with the need for rescreening because of the aging population. Future screening programs may benefit from the inclusion of more targeted criteria in order to increase the number of detected AAAs.
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